The effect of obesity on outcome of unrelated cord blood transplant in children with malignant diseases.

Department of Pediatrics, Division of Pediatric Hematology/Oncology, Pediatric Stem Cell Transplant Program, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA.
Bone marrow transplantation (Impact Factor: 3.47). 12/2010; 46(10):1309-13. DOI: 10.1038/bmt.2010.312
Source: PubMed

ABSTRACT Obesity has become a pandemic, affecting both children and adults. We sought to determine the effect of obesity among 200 children who were prospectively enrolled on a multicenter cord blood transplant (CBT) trial. All patients received myeloablative preparative regimens. Children were classified into groups according to body mass index percentile. Normal weight was defined as body mass index between the 5th and 85th percentile (n=117), overweight between the 85th and 95th percentile (n=35) and obesity above 95th percentile (n=39) for age and gender. A total of 55 patients (27%) had AML, 113 patients (57%) had ALL and 32 patients (16%) had other malignant diseases. There was no evidence for a difference in all major characteristics among the groups. Time to neutrophil and platelet engraftment, TRM, risk of acute GVHD, disease-free survival and OS were not significantly different in overweight or obese patients compared with normal weight patients. There was a trend towards increased risk of chronic GVHD in obese patients (P=0.05) compared with normal weight patients. In conclusion, there is insufficient evidence from this sample that obesity has an effect on multiple outcomes after unrelated CBT in children with malignant diseases.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is an important public health problem that may influence the outcomes of hematopoietic cell transplantation (HCT). We studied 898 children and adults receiving first-time allogeneic hematopoietic SCTs between 2004 and 2012. Pretransplant body mass index (BMI) was classified as underweight, normal weight, overweight or obese using the WHO classification or age-adjusted BMI percentiles for children. The study population was predominantly Caucasian, and the median age was 51 years (5 months-73 years). The cumulative 3-year incidence of nonrelapse mortality (NRM) in underweight, normal weight, overweight and obese patients was 20%, 19%, 20% and 33%, respectively. Major causes of NRM were acute and chronic GVHD. The corresponding incidence of relapse was 30%, 41%, 37% and 30%, respectively. Three-year OS was 59%, 48%, 47% and 43%, respectively. Multivariate analysis showed that obesity was associated with higher NRM (hazard ratio (HR) 1.43, P=0.04) and lower relapse (HR 0.65, P=0.002). Pretransplant plasma levels of ST2 and TNFR1 biomarkers were significantly higher in obese compared with normal weight patients (P=0.04 and P=0.05, respectively). The increase in NRM observed in obese patients was partially offset by a lower incidence of relapse with no difference in OS.Bone Marrow Transplantation advance online publication, 22 December 2014; doi:10.1038/bmt.2014.280.
    Bone Marrow Transplantation 12/2014; 50(3). DOI:10.1038/bmt.2014.280 · 3.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The rising incidence of pediatric obesity may significantly impact bone marrow transplantation (BMT) outcomes. We analyzed outcomes in 3687 children who received cyclophosphamide (CY) based BMT regimens for leukemias between 1990 and 2007 worldwide. Recipients were classified according to age-adjusted body mass index (BMI) percentiles as underweight (UW), at risk of UW (RUW), normal, overweight (OW), or obese. Median age and race were similar in all groups. Sixty-one percent of obese children were from US/Canada. Three-year relapse-free and overall survival ranged from 48% to 52% (p=0.54) and 55% to 58% (p=0.81) across BMI groups. Three-year leukemia relapse were 33%, 33%, 29%, 25% and 21% in the UW, RUW, normal, OW and obese groups, respectively (p<0.001). Corresponding cumulative incidences for transplant related mortality (TRM) were 18%, 19%, 21%, 22% and 28% (p<0.01). Multivariate analysis demonstrated a decreased risk of relapse compared to normal BMI (RR 0.73, p<0.01) and a trend towards higher TRM (1.28, p=0.014). BMI in children is not significantly associated with different survival after BMT for hematologic malignancies. Obese children experience less relapse post-transplant compared to children with normal BMI, however this benefit is offset by excess in TRM.
    Blood 04/2014; 123(22). DOI:10.1182/blood-2013-03-490334 · 9.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The impact of being overweight on outcome after hematopoietic SCT (HSCT) is controversial. We performed meta-analyses to evaluate the impact of being overweight on acute graft-versus-host disease (aGVHD) risk and survival. Original data were obtained from MEDLINE, and studies that evaluated being overweight before transplantation in recipients as a risk factor for aGVHD or a prognostic factor for overall survival (OS) were extracted. Study-specific relative risks on the log scale comparing overweight with non-overweight patients were used to obtain a pooled RR with 95% confidence interval (CI). We identified 8 studies of aGVHD and 21 of OS. In allogeneic HSCT, the meta-analysis determined statistically significant associations of overweight recipients with aGVHD risk and OS. Meta-analysis of the 8 studies of aGVHD indicated that the RR for overweight to non-overweight patients was 1.186 (95% CI: 1.072-1.312). Regarding OS, meta-analysis of 11 allogeneic HSCT studies indicated that the RR for overweight to non-overweight patients was 1.163 (1.009-1.340). Our results indicate that being overweight before transplantation in recipients is associated with a high aGVHD rate and worse survival after allogeneic HSCT. Potential heterogeneity especially in adult/pediatric patients limits the interpretability of our finding. Further, well-designed large cohort studies are warranted.Bone Marrow Transplantation advance online publication, 19 August 2013;. doi:10.1038/bmt.2013.128.
    Bone marrow transplantation 08/2013; 49(1). DOI:10.1038/bmt.2013.128 · 3.47 Impact Factor

Full-text (2 Sources)

Available from
Mar 31, 2015